Jun 09, 2020 / 07:50PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ultragenyx here with us today. And we have Emil Kakkis, CEO.
Questions and Answers:
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VPWith that, Emil, maybe to start, you have multiple events set to play out this year with advancement of your gene therapy portfolio in addition to commercial launches. Could you just walk us through the catalyst path for maybe the next 12 months with regard to your portfolio?
Emil D. Kakkis - Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Sure, Salveen. Thanks for speaking with me today, and I'll give you kind of an update of where the catalyst [work] for the coming year. It's already June of the year, and it's been quite a year, from COVID and everything else going on in the world. There's been a lot of distractions and pain and suffering. But fortunately
Trustpilot
